Literature DB >> 17628781

[Optimizing treatment of advanced urologic malignancies].

A Heidenreich1, C H Ohlmann, E Ozgür, D Pfister, D Sahi, D Thüer, U H Engelmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17628781     DOI： 10.1007/s00120-007-1396-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  24 in total

Review 1.  Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review.

Authors:  Dimitrios Pectasides; Melina Pectasides; Maria Nikolaou
Journal:  Eur Urol       Date:  2005-04-07       Impact factor: 20.096

Review 2.  The ephrins and Eph receptors in angiogenesis.

Authors:  Nikki Cheng; Dana M Brantley; Jin Chen
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

3.  Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia.

Authors:  Michael Fiegl; Matthias Juergens; Wolfgang Hiddemann; Jan Braess
Journal:  Leuk Res       Date:  2006-08-30       Impact factor: 3.156

Review 4.  Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.

Authors:  Axel Heidenreich; Carsten H Ohlmann
Journal:  Expert Rev Anticancer Ther       Date:  2004-12       Impact factor: 4.512

5.  Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Authors:  Yan C Wang; Dejan Juric; Brian Francisco; Ron X Yu; George E Duran; Kevin G Chen; Xin Chen; Branimir I Sikic
Journal:  Genes Chromosomes Cancer       Date:  2006-04       Impact factor: 5.006

6.  Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

Authors:  S G Patterson; S Wei; X Chen; D A Sallman; D L Gilvary; B Zhong; J Pow-Sang; T Yeatman; J Y Djeu
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.

Authors:  Donald S Crain; Christopher L Amling; Christopher J Kane
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.

Authors:  H Miyake; S Hara; S Arakawa; S Kamidono; I Hara
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

10.  Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer.

Authors:  A Katagiri; Y Tomita; T Nishiyama; M Kimura; S Sato
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.